[1]李晓飞,陈峻江△.普萘洛尔联合马来酸噻吗洛尔治疗不同分型婴幼儿血管瘤疗效观察[J].陕西医学杂志,2020,49(4):498-501.
　LI Xiaofei,CHEN Junjiang..Efficacy of oral propranolol combined with topical timolol maleate on different patterns of infantile hemangioma[J].,2020,49(4):498-501.
点击复制

普萘洛尔联合马来酸噻吗洛尔治疗不同分型婴幼儿血管瘤疗效观察
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年4期
页码:
498-501
栏目:
药物与临床
出版日期:
2020-04-05

文章信息/Info

Title:
Efficacy of oral propranolol combined with topical timolol maleate on different patterns of infantile hemangioma
文章编号:
DOI:10.3969/j.issn.10007377.2020.04.028
作者:
李晓飞1; 陈峻江2△
1.锦州医科大学附属第三医院(锦州 121000); 2.锦州医科大学附属第一医院(锦州 121000)
Author(s):
LI Xiaofei; CHEN Junjiang.
The Third Affiliated Hospital of Jinzhou Medical University(Jinzhou 121000)
关键词:
血管瘤;  普萘洛尔;  马来酸噻吗洛尔;  不同分型;  婴幼儿
Keywords:
Hemangioma;  Propranolol;  Timolol maleate;  Different patterns;  Infant
分类号:
R725.4
文献标志码:
A
摘要:
目的:观察普萘洛尔联合马来酸噻吗洛尔治疗不同分型婴幼儿血管瘤(IH)的疗效差异。方法:将146例IH患儿根据瘤体侵及深度分为浅表组38例、深部组59例、混合组49例,所有患儿均接受口服普萘洛尔联合局部外用马来酸噻吗洛尔治疗6个月或病变完全消失。以治疗2、4、6个月为评定时间点,对比三组患儿病灶颜色、大小视觉模拟评分(VAS)和治疗6个月后临床疗效的差异,并记录不良反应。结果:所有患儿均完成治疗,用药时间4～6个月。治疗期间三组患儿病灶颜色及大小VAS评分均呈显著上升趋势(P<0.01),三组间比较差异有统计学意义(P<0.01),其中浅表组和混合组病灶颜色及大小改善程度优于深部组; 治疗6个月后临床疗效三组间比较差异有统计学意义(P<0.05),其中浅表组最高为89.5%,深部组最低为64.4%; 三组患儿治疗期间不良反应发生率为6.2%,三组间不良反应发生率比较差异无统计学意义(P>0.05)。结论:口服普萘洛尔联合局部外用马来酸噻吗洛尔治疗婴幼儿血管瘤安全有效,其中浅表型和混合型疗效优于深部型。
Abstract:
Objective:To observe the efficacy of oral propranolol combined with topical timolol maleate on different patterns of infantile hemangioma(IH).Methods:146 infants with IH were classified as superficial group(38 cases),deep group(59 cases)and mixed group(49 cases)according to the depth of tumor invasion.All infants were treated with oral propranolol combined with topical timolol maleate for 6 months or until the hemangioma completely regressed.The changes of lesion color and size visual analogue scale(VAS)in three groups were compared and analyzed at 2,4 and 6 months,and the therapeutic outcome after 6 months were compared between three groups.The adverse reactions of infants during treatment were recorded.Results:All the infants completed the treatment and the therapy duration was 4 to 6 months.The color and size VAS scores of the three groups showed a significant upward trend(P<0.01),and there were significant differences between the three groups(P<0.01).The improvement of color and size in superficial group and mixed group was better than that in deep group.There were statistical differences in therapeutic outcome between the three groups after 6 months(P<0.05).The highest clinical effective rate in superficial group was 89.5%,and the lowest in deep group was 64.4%.The incidence of adverse reactions during treatment in the three groups was 6.2%,and there was no statistical difference in the incidence of adverse reactions between the three groups(P>0.05).Conclusion:The treatment of oral opropranolol combined with topical timolol maleate for infantile hemangioma is effective and safe,and the curative effect of superficial and mixed hemangioma is better than that of deep hemangioma.

参考文献/References:

[1] 陶 超,徐仙赟,刘海金,等.不同β-受体阻滞剂治疗婴幼儿型血管瘤临床应用的研究进展[J].中华小儿外科杂志,2019,40(3):272-276.
[2] 于 倩,许 鹏,黄惠真,等.单纯口服普萘洛尔与联合外用0.5%马来酸噻吗洛尔乳膏治疗婴幼儿血管瘤效果的随机对照研究[J].中华整形外科杂志,2019,35(2):137-141.
[3] Chang SJ,Yu W,Gu Y,et al.Location of infantile hemangioma is a predictor of volumetric sequelae after involution [J].J Dermatol,2019,46(5):371-375.
[4] 李 巍,陈 曦,刘晓红,等.噻吗洛尔滴眼液外用治疗婴儿血管瘤40例[J].陕西医学杂志,2015,44(10):1406-1407.
[5] Al-Haddad C,El Salloukh NA,El Moussawi Z.β-blockers in the treatment of periocular infantile hemangioma [J].Curr Opin Ophthalmol,2019,30(5):319-325.
[6] 佟 爽,王绪凯,孙 旭,等.普萘洛尔联合马来酸噻吗洛尔治疗严重婴幼儿腮腺区混合型血管瘤的临床观察[J].中国美容整形外科杂志,2018,29(12):726-729.
[7] Achauer BM,Chang CJ,Vander Kam VM.Management of hemangioma of infancy:review of 245 patients [J].Plast Reconstr Surg,1997,99(5):1301-1308.
[8] Léauté-Labrèze C,Dumas De la Roque E,Hubiche T,et al.Propranolol for severe hemangiomas of infancy [J].N Engl J Med,2008,358(24):2649-2651.
[9] 陈 彬,仇雅璟,林晓曦.婴幼儿血管瘤外用药物治疗研究进展[J].中华整形外科杂志,2019,35(5):502-506.
[10] Huang J,Jiang D,Zhao S,et al.Propranolol suppresses infantile hemangioma cell proliferation and promotes apoptosis by upregulating miR-125b expression [J].Anticancer Drugs,2019,30(5):501-507.
[11] 张 蕾,程沫沙,白晓峰,等.口服普萘洛尔与局部外用马来酸噻吗洛尔联合应用治疗婴幼儿腮腺区血管瘤疗效研究[J].中国实用口腔科杂志,2018,11(3):172-175.
[12] 吴 奇,李养群.婴幼儿血管瘤的发生机制及治疗研究进展[J].医学综述,2018,24(21):4270-4275.
[13] Cheirif-Wolosky O,Novelo-Soto AD,Orozco-Covarrubias L,et al.Infantile hemangioma:an update in the topical and systemic treatments [J].Bol Med Hosp Infant Mex,2019,76(4):167-175.
[14] 魏景健,司亚萌,张爱侠,等.马来酸噻吗洛尔滴眼液治疗婴幼儿增殖期浅表血管瘤的疗效[J].中华医学美学美容杂志,2019,25(3):248-249.
[15] Danarti R,Ariwibowo L,Radiono S,et al.Topical timolol maleate 0.5% for infantile hemangioma:its effectiveness compared to ultrapotent topical corticosteroids - A single-center experience of 278 cases [J].Dermatology,2016,232(5):566-571.
[16] Ding A,Gong X,Li J,et al.Role of ultrasound in diagnosis and differential diagnosis of deep infantilehemangioma and venous malformation [J].J Vasc Surg Venous Lymphat Disord,2019,7(5):715-723.
[17] Takechi T,Kumokawa T,Kato R,et al.Role of ultrasound in diagnosis and differential diagnosis of deep infantile hemangioma and venous malformation [J].J Clin Pharmacol,2018,58(10):1361-1370.
[18] 鲁红松,蒋 冠.0.5%噻吗洛尔滴眼液治疗浅表型婴幼儿血管瘤的疗效观察[J].临床皮肤科杂志,2017,46(2):137-138.
[19] 张凯驰,徐大朋,程沫沙,等.马来酸噻吗洛尔和普萘洛尔治疗婴幼儿表浅型血管瘤的疗效分析[J].中国口腔颌面外科杂志,2017,15(6):529-533.

更新日期/Last Update: 2020-04-13